/l, Hgb 12.1 g/dl, and platelet count of 223 Â 10 9 /l, although BM biopsy showed 20% cellularity with almost 100% involvement by HCL.
In June 1985, the patient was started on daily INFa again due to a decline of Hgb to 9.4 mg/dl and the platelet count to 169 Â 10 9 /l. He continued to receive 10 mg prednisone and 5 mg Coumadin daily. There was an improvement with this therapy in peripheral blood accounts. INFa was stopped in September 1986 due to a drop of Hgb to 10.4, which was thought to be due to INFa-associated autoimmune hemolysis. Within a month, Hgb rose to 12.4 g/dl. Owing to persistent heavy leukemic infiltrate in the BM, the patient received deoxycorformycin at 4 mg/m 2 i.v. every other week in February 1987 for 6 months. However, no significant response was observed, and the patient became transfusion dependent. In October 1987, treatment with fludarabine, 30 mg/m 2 /day for five days, was started. After 5 courses, the patient's Hgb and platelet count steadily improved, but he remained neutropenic (WBC 1.1 Â 10 9 /l with neutrophils 56%). From September 1989 to May 1991, the patient was treated with two courses of 2-chlorodeoxyadenosine (2-CdA) therapy at 4 mg/m 2 daily. This resulted in good response, and the remission lasted for a year. Then his symptoms returned and hairy cells appeared in the BM. He received a full 7-day, uneventful course of 2-CdA. Following that treatment, he was found to have only occasional hairy cells in BM. In April 1993, his CBC data showed WBC 3.8 Â 10 9 /l, Hgb 15.1 g/dl, and platelets 228 Â 10 9 /l. He remained asymptomatic with satisfactory peripheral blood indices for more than 7 years. However, in April 1998 his Hgb dropped to 11.8 g/dl and platelets to 125 Â 10 9 /l. He received 2-CdA at 7 mg/m 2 daily for 4 days, which produced partial remission.
In August 1999, the patient received eight doses of Rituximab at 375 mg/m 2 weekly, which resulted in a 1-year clinical remission. He then was found to have 30% hairy cells in the BM. Subcutaneous injection with Enbrel, an anti-TNF receptor reagent, was initiated but stopped 3 months later due to lack of response.
At the beginning of 2001, he was treated with a combination of 2-CdA and Rituximab. The 2-CDA dose was reduced by > 1 3 , and Rituximab dose was started at 275 mg/m 2 and gradually increased to 500 mg/m 2 (eight doses in total). He tolerated the treatment well and had no complications, and his counts recovered to normal with his BM free of hairy cells.
In April 2002, he was found to have 50% hairy cells in the BM, and peripheral blood data showed WBC 8.6 Â 10 9 /l with 13% neutrophils and 87% lymphocytes, Hgb 12.2 g/dl, and platelet count of 143 Â 10 9 /l. He received Campath therapy for 4 weeks, but only partially responded, with his peripheral counts remaining low (WBC 0.8 Â 10administered for 3 days, which reduced his WBC to 4.8 Â 10 9 /l with 98% lymphocytes. However, he remained severely neutropenic and thrombocytopenic. In February 2003, the patient had lung infection with aspergillus that was controlled with oral voriconazole followed by the addition of intravenous caspofungin.
In March 2003, the patient had a peripheral WBC of 6 Â 10 9 /l with 99% hairy cells and only 1% neutrophils. He received immunoconjugate therapy at National Cancer Institute with BL-22, an anti-CD22 Pseudomonas endotoxin reagent, at maximum doses (40 mg/kg every other day for 3 days). He tolerated the treatments without any significant side effects and completed eight courses of therapy by the end of October 2003. With each treatment, there was a transient reduction in hairy cells. He maintained an absolute neutrophil count in the range of 1.5-2 Â 10 9 /l, Hgb 9-10 g/dl, and platelet count 30-40 Â 10 9 /l. He was transfusion independent. Unfortunately, neutralizing antibody against the anti-CD22 endotoxin reagent was detected in November and he was taken off the therapy. The patient began receiving Rituximab with GM-CSF in early 2004, and was being evaluated for BM transplantation at the time this was written.
During the course of the disease, which spanned 21 years, the patient had good quality of life, although his BM was rarely clear of the HCL cells. The patient has had 61 BM biopsies and/or aspirations carried out at MD Anderson Cancer Center alone. The diagnosis of HCL was confirmed on numerous occasions by positive TRAP stains and a typical immunophenotype by flow cytometry (CD25 þ , CD20 þ , CD103 þ , CD11c þ ). One of the unusual findings was that some leukemic cells were unusually large and had lobulated nuclear contours (Figure 1) . The large cells were approximately 1.5 times the size of the average hairy cells. The presence of these large cells raised the question whether the HCL had been transformed to a high-grade lymphoma. We retrospectively reviewed available previous pathology materials and found that similar large and lobulated cells had been present earlier in the disease course (Table 1) . Despite the presence of large hairy cells, the patient showed partial or good response to various therapies. In September 1989, for example, his BM had 90% of cellularity with 75% leukemic infiltrate, and 80% of hairy cells were large, yet he had clinic remission for more than 7 years after 2-CdA therapy.
Case #2
The patient was a 55-year-old man who had a 17-year history of HCL disease. His recent BM biopsy taken in June 2003 was found to have, in addition to average-sized HCL cells, a significant number of large hairy cells (71% of total leukemic cells) (Figure 1c ). Retrospective review of available previous BM specimens obtained yearly at our institution revealed 6, 29, 44, 25, and 24% of large hairy cells from 1998 to 2002. Immunophenotype had been consistently typical for HCL. The disease responded well to the treatments with splenectomy, INF and 2-CdA, but the patient also had multiple relapses. At the time this report was written, he was receiving 2-CdA therapy.
Case #3
A 58-year-old man was initially diagnosed with HCL in May 2001 and treated with 2-CdA, which resulted in a complete remission that lasted for one and a half years. He then presented at MD Anderson Cancer Center. His initial diagnostic material was not available to us, but his BM biopsy performed at our institution 2 years after diagnosis showed relapse of disease with 70% of leukemic infiltrate in an 80% cellular marrow. Smears showed that 57% of nucleated BM cells were hairy cells, of which 60% were unusually large (Figure 1d ). Flow cytometry demonstrated an immunophenotype consistent with HCL (CD19 þ , CD25 þ , CD11c þ , and CD103 þ ). At the time this report was written, he was receiving Rituximab.
Discussion
We presented three cases of HCL with large hairy cells. The percentage of large cells appeared to increase over time during the disease course. However, the significance of the presence of large hairy cells is not clear. Transformation of HCL to EpsteinBarr virus (EBV)-positive aggressive B-cell lymphoma has been reported, 4 but the lymphoma might have been a clonally independent disease. We performed in situ hybridization on the three cases and in none of them were the hairy cells positive for EBV-encoded small RNA. Recent karyotyping on the three cases showed del(1)(p31p12), inv(6)(p21.1p23), and diploidy, respectively. It is not clear whether the abnormal karyotype in the two cases resulted from progression or was present at the early stages. The presence of large cells may not be necessarily an indication that the disease has become more aggressive. As seen in our cases, a good response to conventional HCL therapies can still be achieved even with high percentage of large hairy cells. Therefore, we conclude that the presence of large hairy cells should not be interpreted as 'transformation to large cell lymphoma' when other features such as immunophenotypic results of flow cytometry are still typical of HCL. Gemtuzumab ozogamicin (GO, Mylotargt), a novel immunoconjugate therapy for acute myeloid leukemia (AML), consists of a humanized anti-CD33 antibody conjugated to a calicheamicin-g1 derivative, N-acetyl gamma calicheamicin dimethyl hydrazine. After internalization, the cytotoxic moiety is released and activated to a highly reactive species that ultimately causes cell death.
1 GO alone induces remissions in approximately 30% of adults with CD33 þ , relapsed AML. 2 The mechanisms underlying GO resistance are incompletely understood; however, efflux of the calicheamicin moiety by P-glycoprotein (Pgp) and, to a lesser extent, multidrug resistance protein (MRP), has been implicated. 3 Breast cancer resistance protein (BCRP/ABCG2), another member of the adenosine triphosphate-binding cassette (ABC) family of transporters, is widely expressed in normal tissues, including primitive hematopoietic stem cells. Evidence to date suggests that BCRP mainly serves to protect cells from xenobiotic toxins, although additional functions in stem cell populations are discussed. 4 ,5 BCRP confers resistance to certain chemotherapeutic agents; however, the substrate specificity in cells containing a mutation at codon 482 (R482T or R482G) differs somewhat from cells expressing wild-type protein. 4, 5 BCRP mRNA and protein are variably expressed in AML. 5, 6 So far, only wild-type BCRP (ie arginine at codon 482) has been
